Tarsus Pharmaceuticals, Inc.
TARS
Clasificación en acciones
#4559
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Precio por acción
$70.49
Capitalización bursátil
$3.30B
Cambio (1 día)
-0.02%
Cambio (1 año)
2.60%
País
US
Comercio Tarsus Pharmaceuticals, Inc. (TARS)
Categoría
Healthcare
Historial del precio de la acción de Tarsus Pharmaceuticals, Inc. (TARS)
Precio más alto de cierre: $72.13 el 2026-10-01
Precio más bajo de cierre: $21.51 el 2020-10-01
Precio más bajo de cierre: $21.51 el 2020-10-01
Historial del precio de la acción de Tarsus Pharmaceuticals, Inc. desde 2020 hasta 2026
Desempeño anual del precio de la acción
| Año | Rendimiento |
|---|---|
| 2026 (TTM) | -13.75% |
| 2025 | 54.26% |
| 2024 | 182.67% |
| 2023 | 21.69% |
| 2022 | -38.83% |
| 2021 | -32.39% |
| 2020 | 0.00% |
Precio de la acción de empresas similares o competidoras
| Empresa | Precio de la acción | Cambio 1a% | País |
|---|---|---|---|
| $523.31 | 22.71% |
US
|
|
| $237.47 | 784.43% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $874.99 | 7.47% |
NL
|
|
| $287.83 | 1.13% |
BE
|
